{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-23-039073","form_type":"8-K","ticker":"ERNA","cik":"0000748592","company_name":"Ernexa Therapeutics Inc.","filed_at":"2023-08-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:36.592904+00:00","generated_at":"2026-06-11T19:58:01.975059+00:00","sec_items":["3.01","5.02"],"event_type":"regulatory","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"CEO resigns, then reappointed; board resignations trigger Nasdaq non-compliance","bullets":["CEO Dr. Angel resigned Aug 4 citing board's exclusion from business dev; rescinded Aug 8, reappointed Aug 9.","Directors Binder and Wagner resigned Aug 8; Board reduced to two members (Wexler, Fiore).","Nasdaq notified non-compliance with independent director, audit & compensation committee rules.","Company has 45 days to submit compliance plan; up to 180-day extension possible if plan accepted.","Company actively searching for new directors to fill vacancies and regain compliance."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-23-039073","json":"https://secwatch.observer/filing/0001140361-23-039073.json","markdown":"https://secwatch.observer/filing/0001140361-23-039073.md","text":"https://secwatch.observer/filing/0001140361-23-039073.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/748592/000114036123039073/0001140361-23-039073-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/748592/000114036123039073/brhc20057343_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T19:58:01.975059+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1feb5e06f4","claim":"Richard W. Wagner resigned as Director at Ernexa Therapeutics Inc..","evidence_excerpt":"On August 8, 2023, Mr. Brant C. Binder and Dr. Richard W. Wagner resigned from the Board","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/748592/000114036123039073/0001140361-23-039073-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"4114dec462","claim":"Brant C. Binder resigned as Director at Ernexa Therapeutics Inc..","evidence_excerpt":"On August 8, 2023, Mr. Brant C. Binder and Dr. Richard W. Wagner resigned from the Board","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/748592/000114036123039073/0001140361-23-039073-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"5fa80c40b9","claim":"Matthew Angel resigned as President and Chief Executive Officer at Ernexa Therapeutics Inc..","evidence_excerpt":"On August 4, 2023, Dr. Matthew Angel resigned from the Board and as the Company’s President and Chief Executive Officer","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/748592/000114036123039073/0001140361-23-039073-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"President and Chief Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"9e9879880a","claim":"Matthew Angel was appointed as President and Chief Executive Officer at Ernexa Therapeutics Inc..","evidence_excerpt":"the Board reappointed Dr. Angel as the Company’s President and Chief Executive Officer","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/748592/000114036123039073/0001140361-23-039073-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"reappointed"},{"label":"Role","value":"President and Chief Executive Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}